Innate immune function during antineoplastic treatment is associated with 12-months survival in non-small cell lung cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Innate immune function during antineoplastic treatment is associated with 12-months survival in non-small cell lung cancer. / Ryssel, Heidi; Egebjerg, Kristian; Nielsen, Susanne Dam; Lundgren, Jens; Pøhl, Mette; Langer, Seppo W.; Kjaer, Andreas; Ostrowski, Sisse Rye; Fischer, Barbara Malene.
In: Frontiers in Immunology, Vol. 13, 1024224, 2022, p. 1-12.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Innate immune function during antineoplastic treatment is associated with 12-months survival in non-small cell lung cancer
AU - Ryssel, Heidi
AU - Egebjerg, Kristian
AU - Nielsen, Susanne Dam
AU - Lundgren, Jens
AU - Pøhl, Mette
AU - Langer, Seppo W.
AU - Kjaer, Andreas
AU - Ostrowski, Sisse Rye
AU - Fischer, Barbara Malene
N1 - Publisher Copyright: Copyright © 2022 Ryssel, Egebjerg, Nielsen, Lundgren, Pøhl, Langer, Kjaer, Ostrowski and Fischer.
PY - 2022
Y1 - 2022
N2 - Introduction: The immune system has proven to be a key player in the progression as well as containment of cancer with new treatment strategies based on immunotherapy targeting this interaction. Assessing immune function could reveal critical information about the immune response to therapeutic interventions, revealing predictive biomarkers for tailored care and precision medicine. Methods: We investigated immune function in 37 patients with inoperable non-small cell lung cancer (NSCLC) undergoing treatment with PD-L1 immune checkpoint inhibitor (ICI), chemotherapy (CT) or chemo-radiotherapy (CT/RT). Blood samples before (day 0) and during therapy (day 7, 21 and 80) were investigated by a standardized immunoassay, TruCulture®. Results: Outcomes revealed a developing innate immune response induced by both immunotherapy and chemotherapy. NSCLC-patients displayed evidence of chronic innate immune activation and exhaustion prior to treatment. This pattern was particularly pronounced during treatment in patients dying within 12-months follow-up. Compared to treatment with CT, ICI demonstrated a higher ex vivo-stimulated release of proinflammatory cytokines. Discussion: These preliminary findings may pave the way for tailored treatment and immune-monitoring.
AB - Introduction: The immune system has proven to be a key player in the progression as well as containment of cancer with new treatment strategies based on immunotherapy targeting this interaction. Assessing immune function could reveal critical information about the immune response to therapeutic interventions, revealing predictive biomarkers for tailored care and precision medicine. Methods: We investigated immune function in 37 patients with inoperable non-small cell lung cancer (NSCLC) undergoing treatment with PD-L1 immune checkpoint inhibitor (ICI), chemotherapy (CT) or chemo-radiotherapy (CT/RT). Blood samples before (day 0) and during therapy (day 7, 21 and 80) were investigated by a standardized immunoassay, TruCulture®. Results: Outcomes revealed a developing innate immune response induced by both immunotherapy and chemotherapy. NSCLC-patients displayed evidence of chronic innate immune activation and exhaustion prior to treatment. This pattern was particularly pronounced during treatment in patients dying within 12-months follow-up. Compared to treatment with CT, ICI demonstrated a higher ex vivo-stimulated release of proinflammatory cytokines. Discussion: These preliminary findings may pave the way for tailored treatment and immune-monitoring.
KW - chemotherapy
KW - immune
KW - immunotherapy
KW - NSCLC
KW - response
UR - http://www.scopus.com/inward/record.url?scp=85144965218&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.1024224
DO - 10.3389/fimmu.2022.1024224
M3 - Journal article
C2 - 36578486
AN - SCOPUS:85144965218
VL - 13
SP - 1
EP - 12
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 1024224
ER -
ID: 332613352